Ul'trazvukovoy monitoring v otsenke effektivnostii bezopasnosti androgenoterapii u patsientov s androgennymdefitsitom i metabolicheskim sindromom

1. Huggins C., Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.J Urol. 2002 Jul;168(1):9-12.

2. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26.

3. Parsons J.K., Carter H.B., Platz E.A., Wright E.J., Landis P., Metter E.J. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2257-60.

4. Hsing A.W., Reichardt J.K., Stanczyk F.Z. Hormones and prostate cancer: current perspectives and future directions. Prostate. 2002 Aug 1;52(3):213-35.

5. Marks L.S., Mazer N.A., Mostaghel E., Hess D.L., Dorey F.J., Epstein J.I., Veltri R.W., Makarov D.V., Partin A.W., Bostwick D.G., Macairan M.L., Nelson P.S. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogo-nadism: a randomized controlled trial. JAMA. 2006 Nov 15;296(19):2351-61.

6. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006 Nov;50(5):935-9.

7. Абдуллаев Н. Х. Влияние метандростиналона на содержание гликогена в печени и некоторые патохимические сдвиги жирового обмена при экспериментальном хроническом токсическом гепатите. //Пробл. Эндокр. и горм. - Т.12. №4. 1996. - С. 106 -110.

8. Гормонотерапия // под редакц. Х. Шамбаха и др. - М., 1988. С. 416.

9. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006 May;23(5):469-80.

10. Лелюк В.Г, Лелюк С.Э. Ультразвуковая ангиология. М.: Видар, 2003.